Next Generation News and Research

RSS

Positive results from Repligen's RG3039 Phase 1 study for spinal muscular atrophy

Repligen Corporation today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).

25 Apr 2012

ASH report urges federal agencies to invest in 7 distinct areas of research

The American Society of Hematology (ASH), the world's largest professional society committed to the study and treatment of blood disorders, today issued a report urging federal agencies to coordinate hematology research funding around seven specific high-need areas that would produce the greatest impact and translate into improvements in patient care in the United States.

25 Apr 2012

Nigeria's first-ever national Vaccine Summit addresses child mortality burden

Nigeria's top government officials, civil society leaders and leaders of private industry resolved today to join forces to expand vaccine access nationwide, a major step in the fight to reduce child mortality in a country with the world's second highest number of child deaths.

24 Apr 2012

Researchers develop small endoscopic device fitted with femtosecond laser scalpel

Whether surgeons slice with a traditional scalpel or cut away with a surgical laser, most medical operations end up removing some healthy tissue, along with the bad. This means that for delicate areas like the brain, throat, and digestive tract, physicians and patients have to balance the benefits of treatment against possible collateral damage.

24 Apr 2012

Latest scientific research in children's health to be presented at PAS meeting

The latest scientific research in children's health will be presented in Boston April 28-May 1 at the Pediatric Academic Societies Annual Meeting. More than 6,500 leaders in academic pediatrics from around the world are expected to attend the meeting at the Hynes Convention Center.

24 Apr 2012

Enrollment complete for In-tunnel SeptRx European PFO Trial in Europe

SeptRx, an emerging medical device company that has developed the SeptRx Intrapocket PFO Occluder (IPO), reported today that it has completed enrollment for its "InterSEPT" (In-tunnel SeptRx European PFO Trial) clinical trial in Europe, and has entered into a partnership with CoRRect Medical GmbH for commercial distribution in Germany and Switzerland of the SeptRx IPO.

23 Apr 2012

MicuRx completes MRX-I Phase 1 trial on MRSA and VRE infection

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the completion of its Phase 1 clinical trial for MRX-I, its first development-stage antibiotic drug candidate.

23 Apr 2012

Updated results from CircuLite’s Synergy miniature ventricular support system clinical study

CircuLite, Inc. today announced that updated clinical data related to the Synergy miniature ventricular support system was presented in two oral presentations and one poster session at the International Society for Heart and Lung Transplantation's 32nd Annual Meeting and Scientific Sessions (ISHLT) in Prague, Czech Republic.

21 Apr 2012

GE Healthcare, NXT2B partner to develop micro-scale radiotracer infrastructure

GE Healthcare, a unit of General Electric Company, and NXT2B, a privately owned venture capital company, today announced they have entered into a joint financing agreement with the goal of developing a micro-scale radiotracer infrastructure including cyclotron and PET tracer production.

20 Apr 2012

Viewpoints: Bishops find fault with GOP budget; Pelosi on court's role in health law

In February, the Catholic Church attempted to impose its opposition to birth control on its employees, upsetting Democrats and the left. This week, the Church is criticizing Republicans, acting in the highest tradition of its social mission by speaking out against spending cuts on programs for the poor.

20 Apr 2012

Merkin Family Foundation pledges new commitment to the Broad Institute

The Merkin Family Foundation today announced a commitment to the Broad Institute of Harvard and MIT to establish the Merkin Institute Fellows, a program that will support some of the most promising and ambitious scientists pursuing bold research at the Broad Institute.

19 Apr 2012

GSK, Epizyme and Constellation to develop next generation of epigenetic drugs for cancer

Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.

19 Apr 2012

Positive results from CrystalGenomics’ CG100649 Phase 2b OA study

CrystalGenomics, Inc., a biopharmaceutical company headquartered in Korea, has just announced positive results from the Phase 2b osteoarthritis (OA) study of the CG100649, CrystalGenomics' next-generation NSAID candidate.

19 Apr 2012

BCCA, UBC scientists identify new breast cancer genes

Scientists at the BC Cancer Agency and University of British Columbia have identified new breast cancer genes that could change the way the disease is diagnosed and form the basis of next-generation treatments.

19 Apr 2012

Bruker introduces new products at Analytica 2012

At Analytica 2012, Bruker today announced several new product introductions for the research, industrial and applied markets, designed to deliver confident analyses with increased sensitivity, specificity and productivity, and to push the boundaries of advanced molecular and materials research applications.

18 Apr 2012

Allied Healthcare announces Coridon license to vector technology

Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.

17 Apr 2012

Bruker launches novel AVANCE III HD NMR spectrometer

At the Experimental Nuclear Magnetic Resonance Conference (ENC) 2012, Bruker introduces the novel AVANCE III HD NMR spectrometer.

17 Apr 2012

UM hosts symposium on next generation characterization tools for therapeutic proteins

In a concerted effort to boost regional collaboration on developing new protein drug and diagnostics, the University of Maryland (UM) School of Pharmacy has hosted the first Interdisciplinary Symposium on Next Generation Characterization Tools for Therapeutic Proteins.

16 Apr 2012

Biologists decipher novel functions of metal-binding molecule nicotianamine

In order to survive, plants should take up neither too many nor too few minerals from the soil. New insights into how they operate this critical balance have now been published by biologists at the Ruhr-Universit-t in a series of three papers in the journal The Plant Cell. The researchers discovered novel functions of the metal-binding molecule nicotianamine.

16 Apr 2012

Missing tool helps sperm and eggs develop exactly 23 chromosomes each

Researchers at the University of California, Davis have discovered a key tool that helps sperm and eggs develop exactly 23 chromosomes each. The work, which could lead to insights into fertility, spontaneous miscarriages, cancer and developmental disorders, is published April 13 in the journal Cell.

16 Apr 2012